-
Pharma and Health from Ingredients to Pills: Cancer Therapeutics Today(2)
Lin Zhang
July 28, 2020
In 2015, the advantages of the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas)9-mediated genome modification......
-
Merck and 10x Genomics launch new option for CRISPR research
expresspharma
June 12, 2020
The companies will work together as part of 10x Genomics’ 10x Compatible Partnership Program, a global ecosystem of technologies and solutions that provide customers with the ability to enhance their unique research applications and accelerate discovery.
-
Scientists aim gene-targeting breakthrough against COVID-19
worldpharmanews
June 05, 2020
A team of scientists from Stanford University is working with researchers at the Molecular Foundry.
-
Regeneron and Intellia to develop new haemophilia therapies
pharmaceutical-technology
June 03, 2020
Regeneron Pharmaceuticals has expanded its ongoing partnership with Intellia Therapeutics for the development of therapies for haemophilia A and B.
-
Regeneron, Intellia Expand CRISPR/Cas9 Alliance
contractpharma
June 02, 2020
Provides Regeneron with rights to develop additional CRISPR/Cas9-based therapeutic targets and to jointly develop potential products for hemophilia A and B.
-
Utilising CRISPR could reduce contamination in recombinant-protein drugs
europeanpharmaceuticalreview
May 05, 2020
Researchers have used CRISPR-Cas to edit the genes of contaminating proteins in mammalian cells used to produce recombinant-protein drugs, which could reduce costs and strengthen quality.
-
Merck awarded second US patent for CRISPR Gene-Editing Technology
expresspharma
April 09, 2020
Merck announced that the United States Patent and Trademark Office has granted the company’s patent for CRISPR-chrom technology.
-
New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus
worldpharmanews
March 17, 2020
CRISPR-based genetic screens have helped scientists identify genes that are key players in sickle-cell anemia, cancer immunotherapy, lung cancer metastasis, and many other diseases.
-
Merus Announces Chief Executive Officer Transition
americanpharmaceuticalreview
December 19, 2019
Merus announced Dr. Ton Logtenberg will step down as CEO, President, Principal Financial Officer and Director of the Company on December 31, 2019.
-
Gene-targeted cancer drugs, slow release overcome resistance
worldpharmanews
September 17, 2019
Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, protein engineering and ...